VALIANTLAB — Valiant Laboratories Income Statement
0.000.00%
Last trade - 00:00- IN₹5.00bn
- IN₹5.45bn
- IN₹1.33bn
- 27
- 18
- 61
- 25
Annual income statement for Valiant Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | PROSPECTUS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 2,082 | 3,339 | 1,821 | 1,334 |
| Cost of Revenue | ||||
| Gross Profit | 407 | 566 | 138 | 168 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 1,797 | 3,004 | 1,924 | 1,402 |
| Operating Profit | 285 | 335 | -104 | -67.7 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 302 | 381 | -7.7 | -15.1 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 227 | 290 | 3.2 | -22 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 227 | 290 | 3.2 | -22 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 227 | 290 | 3.2 | -22 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 14 | 8.91 | 0.084 | -0.51 |
| Dividends per Share |